Immuneering Co-Founder & CEO Ben Zeskind discusses the future of the third generation MEK inhibitor atebimetinib, which has shown promising data in first line pancreatic cancer
He goes over data presented at ASCO and discusses the company's pivotal trial, which is up and running and will read out in 2028. Plus, expansion into lung cancer in combination with a PD-1.









.png)